bioRxivImmunology
Tumors induce de novo steroid biosynthesis in T cells to evade immunity
B. Mahata, J. Pramanik, L. v. d. Weyden, K. Polanski, G. Kar, A. Riedel, X. Chen, N. A. Fonseca, K. Kundu, L. S. Campos, E. Ryder, G. Duddy, I. Walczak, K. Okkenhaug, D. J. Adams, J. D. Shields, S. A. Teichmann
Abstract
Tumors subvert immune cell function to evade immune responses, yet the complex mechanisms driving immune evasion remain poorly understood. Here we show that tumors induce de novo steroidogenesis in T lymphocytes to evade anti-tumor immunity. Using a novel transgenic steroidogenesis-reporter mouse line we identify and characterize de novo steroidogenic immune cells. Genetic ablation of T cell steroidogenesis restricts primary tumor growth and metastatic dissemination in mouse models. Steroidogenic T cells dysregulate anti-tumor immunity, and inhibition of the steroidogenesis pathway was sufficient to restore anti-tumor immunity. This study demonstrates T cell de novo steroidogenesis as a mechanism of anti-tumor immunosuppression and a potential druggable target.
- organism: mouse
- research focus: cancer & tumor microenvironment
- research focus: drug response / drug discovery
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Differential effects of corticosteroids and anti-TNF on tumor-specific immune responses - implications for the management of irAEs
A. Draghi, T. H. Borch, … M. Donia·bioRxiv·Oct 8, 2018
- Estrogen deprivation triggers an immunosuppressive phenotype in breast cancer cells
D. Huhn, P. Marti-Rodrigo, … O. Fernandez-Capetillo·bioRxiv·Aug 28, 2019
- Cellular selectivity of STING stimulation determines priming of tumor-specific T cell responses
B. Jneid, A. Bochnakian, … N. Manel·bioRxiv·Dec 1, 2021
- Tumour-derived glucocorticoids amplify ROR1 and are exploited with glucocorticoid-resistant ROR1 CAR-T cells
Marc Philipp Schauer, Justus Weber, … Michael Hudecek·bioRxiv·Jan 28, 2025
- Prime-Target neoantigen vaccination unleashes unprecedented T cell immunity within ''cold'' immunosuppressive tumors
Kou Hioki, Marlous Wildemans, … Peter D. Katsikis·bioRxiv·Jan 13, 2026
- Targeting of Cdc42 GTPase in regulatory T cells unleashes anti-tumor T cell immunity
K. W. Kalim, J.-Q. Yang, … F. Guo·bioRxiv·Sep 23, 2021